Publications
Publications
Presentations
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes. Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy. South African Journal of HIV Medicine 2020 ISSN: (Online) 2078-6751, (Print) 1608-9693
A clinical prediction rule for protease inhibitor resistance in patients failing second-line antiretroviral therapy
Karen Cohen, Annemie Stewart, Andre P. Kengne, Rory Leisegang, Marla Coetsee, Shavani Maharaj, Liezl Dunn, Michael Hislop, Gert van Zyl, Graeme Meintjes, Gary Maartens. A clinical prediction rule for protease inhibitor resistance in patients failing second-line antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2019, 80:325–329.
Risk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy
Sumanth Karamchand, Rory Leisegang, Michael Schomaker, Gary Maartens, Lourens Walters, MSc, BA, Michael Hislop, Joel A. Dave, Naomi S. Levitt and Karen Cohen. Risk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Medicine 2016, 95(9).
Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
Graeme Meintjes, Liezl Dunn, Marla Coetsee, Michael Hislop, Rory Leisegang, Leon Regensberg and Gary Maartens. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Research and Therapy 2015, 12:39.
Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study
Richard Court, Rory Leisegang, Annemie Stewart, Henry Sunpath, Richard Murphy, Philip Winternheimer, Mashuda Ally and Gary Maartens. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. BMC Infectious Diseases 2014, 14:664
A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa
Leisegang, R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S. 2013. A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa. PLOS ONE. 2013 February; 8(2).
Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. BMC Health Services Research
Leisegang R, Maartens G, Hislop M, Regensberg L, Cleary S. Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. BMC Health Services Research. 2010 Jul 2; 10 Suppl 1:S3.
Association of antiretroviral therapy adherence and health care costs.
Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. Annals of Internal Medicine. 2010 Jan 5; 152(1):18-25.
Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis
Leisegang R, Cleary S, Hislop M, Davidse A, Regensberg L, Little F, Maartens G. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med. 2009 Dec; 6(12):e1000189. Epub 2009 Dec 1.
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. Journal of Acquired Immune Deficiency Syndromes
Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. Journal of Acquired Immune Deficiency Syndromes. 2009 May 1; 51, 65–71.